BioCanRx Call for Proposals – Full Application
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Tuesday 1st, December 2026
External Deadline: Friday 4th, December 2026
Description
This $6M investment will be aimed at advancing promising cancer immunotherapies and enabling technologies toward the clinic, and supporting the adoption of these therapies into the Canadian healthcare system. Full program details and application materials will be released on Wednesday, June 17, 2026.
This call for research proposals will seek applications to the following funding programs:
Enabling Studies Program
Up to $750,000, up to 3 years, 50% matching required
- BioCanRx will fund up to 50% of total eligible project costs, to a maximum contribution of $750,000. The remaining 50% must be provided as matching funds from eligible partners.
- Prepare and position novel cancer immunotherapies and enabling technologies for clinical testing in patients, including GMP manufacturing and process development. Enabling Studies projects should result in either a complete Health Canada CTA submission packages or Quality (Chemistry and Manufacturing) packages.
- Clinical, Social and Economic Impact (CSEI) Program
Up to $215,000, up to 3 years
- Identify and address the facilitators and barriers to the ultimate adoption and integration of these therapies into Canadian clinical practice and healthcare systems.
Core Facilities Program
Up to $120,000 per year, up to 2 years
- Supports manufacturing or translational research services that support the advancement and production of cancer immunotherapies.
Linked Applications Favoured
CSEI applications may be submitted as standalone projects; however, applications that are linked with Enabling or Clinical Trials proposals currently funded or applying to this competition will be assessed more favourably.
Core facilities will be evaluated on demonstrated evidence of planned collaborations and scope of work across multiple currently funded or proposed Enabling Studies or Clinical Trial projects.
- Letter of Intent (LOI) submission deadline: July 29, 2026
- Full application submission deadline: December 4, 2026
Join us for an informational webinar to learn more about this funding competition.
Date & Time: Thursday, June 25, 2026, 1:00 PM ET Register here.
For more information, visit here
If you have questions please contact Megan Mahoney, Director of Scientific Affairs and Training Programs at memahoney@biocanrx.com.